TrialAnnals of the rheumatic diseases2015

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

Jonathan Kay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.